yes - i would imagine functional rescue would occur even in low doses - thus we may achieve ‘unofficial’ (?) efficacy readouts - or anecdotal patient reported benefits as early as this year if Dr Chen’s/LEI’s RP11 patients make up the Part 1 Cohort.
The more I read of this presentation the more I feel it should have been marked price sensitive - as there’s lots of new info here, with an improved content delivery style.
Pending IND approval, all 3x programs open up to shifting up a gear - I like the objective they used:
”Establish human safety of PYC’s platform technology”
This would headline PYC as a proven solution to the delivery challenge faced by the (RNA) therapeutics industry as a whole
Ann: PYC Corporate Presentation - February 2023, page-8
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
17.5¢ |
Change
0.005(2.94%) |
Mkt cap ! $816.5M | |||
| Open | High | Low | Value | Volume |
| 17.0¢ | 17.5¢ | 17.0¢ | $128.7K | 753.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 257459 | 17.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 17.5¢ | 33594 | 4 |
View Market Depth
| Last trade - 16.10pm 09/10/2024 (20 minute delay) ? |
| PYC (ASX) Chart |